Congressional Research Service Report: 'Generic Drug User Fee Amendments - Background & Reauthorization'
April 29, 2021
April 29, 2021
WASHINGTON, April 29 -- The Congressional Research Service issued the following report (No. R46778) entitled "The Generic Drug User Fee Amendments: Background and Reauthorization" by health policy analyst Agata Bodie:
SUMMARY
The Food and Drug Administration (FDA) regulates the safety, effectiveness, and quality of drugs--both brand name and generic--pursuant to its authorities under the Federal Food, Drug, and Cosmetic Act (FFDCA). Throughout this report, the . . .
SUMMARY
The Food and Drug Administration (FDA) regulates the safety, effectiveness, and quality of drugs--both brand name and generic--pursuant to its authorities under the Federal Food, Drug, and Cosmetic Act (FFDCA). Throughout this report, the . . .